Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 19

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 2
Chunk 19
---
 for the same period ended 2024. The primarily operating expense
for 2025 consists of $ 46,625 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional
fees expenditure were $95,539. During the period ended 2024 research and development expenses amounted to $32,500 constituting the second
largest expense recognized during that quarter.

Other
Income

For
the three months ended June 30 2025, the Company reported a net other expense of $(126,526) whereas in the same period ended 2024 the
Company reported the net other expense of $(22,154). Net other expense for the quarter ended 2025 was primarily driven by the recognition
of a Derivative Loss of $(89,259). For the quarter ended June 30, 2025 the Company also recognized higher interest and amortization expenses
as compared to the quarter ended 2024.

  22  

Net
Loss

The
Company recognized an Operating Loss of $ 40,759 during the three months ended June 30, 2025 whereas the Company recognized an Operating
Loss of $ 107,966 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense
categories other than General and Administrative expenses and rent incurred during the period ended 2024 as compared to the quarter ended
in 2025.

Net
Loss is $ 167,295 for the three months ended June 30, 2025 as opposed to a Net Loss of $130,120 for the same period ended 2024. The difference
is primarily attributable to the recognition by the Company of a Derivative Loss of $(89,295) in 2025.

Nine
months June 30, 2025 comparing with nine months ended June 30, 2024

                                                        (Unaudited)                                                                                               
                                                        Nine                                                                                                      
                                                        2025                                                                                                      
                                                        Amount                                                                                                    
  Net                                                                                                                                                             
  Revenues                                              $                            94,920        53.57        94,920        53.57             -           0.00  
  Revenues,                                                                          82,275        46.43        82,274        46.43             1           0.00  
  Net                                                                               177,195       100.00       177,194       100.00             1           0.00